173 related articles for article (PubMed ID: 36750608)
1. Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Kohagura K; Kojima S; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Sugawara M; Mori H; Tsujita K; Matsui K; Hisatome I; Ohya Y; Kimura K; Saito Y; Ogawa H;
Hypertens Res; 2023 Jun; 46(6):1417-1422. PubMed ID: 36750608
[TBL] [Abstract][Full Text] [Related]
2. Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.
Kojima S; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Sugawara M; Mori H; Tsujita K; Matsui K; Hisatome I; Ohya Y; Kimura K; Saito Y; Ogawa H;
Rheumatology (Oxford); 2022 May; 61(6):2346-2359. PubMed ID: 34605897
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Gupta MK; Singh JA
Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
[TBL] [Abstract][Full Text] [Related]
4. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Hu AM; Brown JN
Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
[TBL] [Abstract][Full Text] [Related]
5. Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease.
Konishi M; Kojima S; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Sugawara M; Mori H; Tsujita K; Matsui K; Hisatome I; Ohya Y; Kimura K; Saito Y; Ogawa H;
Int J Cardiol; 2022 Feb; 349():127-133. PubMed ID: 34864084
[TBL] [Abstract][Full Text] [Related]
6. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
[TBL] [Abstract][Full Text] [Related]
7. Impacts of Febuxostat on Cerebral and Cardiovascular Events in Elderly Patients with Hyperuricemia: Post Hoc Analysis of a Randomized Controlled Trial.
Sugawara M; Kojima S; Hisatome I; Matsui K; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Mori H; Tsujita K; Ohya Y; Kimura K; Saito Y; Ogawa H;
Clin Pharmacol Ther; 2024 Jun; 115(6):1358-1364. PubMed ID: 38389505
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Jackson RL; Hunt B; MacDonald PA
BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
[TBL] [Abstract][Full Text] [Related]
9. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
[TBL] [Abstract][Full Text] [Related]
10. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
11. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Whelton A; MacDonald PA; Chefo S; Gunawardhana L
Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
[TBL] [Abstract][Full Text] [Related]
12. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
[TBL] [Abstract][Full Text] [Related]
13. Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?
Deng JH; Zhong GW; Zhang JX
Ann Palliat Med; 2022 Aug; 11(8):2789-2791. PubMed ID: 35948476
[No Abstract] [Full Text] [Related]
14. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
Wang S
Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
[TBL] [Abstract][Full Text] [Related]
16. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
[TBL] [Abstract][Full Text] [Related]
17. Febuxostat for the treatment of hyperuricaemia in gout.
Robinson PC; Dalbeth N
Expert Opin Pharmacother; 2018 Aug; 19(11):1289-1299. PubMed ID: 30024787
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
[TBL] [Abstract][Full Text] [Related]
19. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Lee JW; Lee KH
Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
[TBL] [Abstract][Full Text] [Related]
20. Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
Kohagura K; Satoh A; Kochi M; Nakamura T; Zamami R; Tana T; Kinjyo K; Funakoshi R; Yamazato M; Ishida A; Sakima A; Iseki K; Arima H; Ohya Y
J Hypertens; 2023 Sep; 41(9):1420-1428. PubMed ID: 37334544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
